Vorapaxar is a platelet aggregation inhibitor used to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
- Mechanism
- Curator reviewed
Vorapaxar inhibits platelet aggregation through the reversible antagonism of protease-activated receptor 1 (PAR-1), also known as thrombin receptor. PARs are a family of G-protein coupled receptors highly expressed on platelets and activated by serine protease activity of thrombin to mediate thrombotic response. By blocking PAR-1 activating, vorapaxar inhibits thrombin-induced platelet aggregation and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Vorapaxar does not inhibit platelet aggregation induced by other agonists such as adenosine diphosphate (ADP), collagen or a thromboxane mimetic.
- Primary indication
- Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD).Curator reviewed · 2 structured indications
- Formula / weight
- C29H33FN2O4 · 492.5817 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2014
- Code names
- MFCD16038876 · ZCE93644N2
- Brand names
Resolves to
ZBGXUVOIWDMMJE-QHNZEKIYSA-NSMILES[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCCWhat you can answer from here — as of September 24, 2026
Which drugs share a target with Vorapaxar, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account